

FEB 12 2009

510(k) Summary

Introduction According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250
317-521-3208

Contact Person: Kelly French

Date Prepared: November 20, 2008

Device Name Proprietary name: Elecsys Toxo IgG CalCheck

Common name: Toxo IgG CalCheck

Classification name: Single (specified) analyte controls (assayed and unassayed)

Predicate device The Elecsys Toxo IgG CalCheck is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalency to the currently marketed Elecsys C-Peptide CalCheck (K040157).

Device Description The Elecsys Toxo IgG CalCheck is a lyophilized product consisting of human anti-Toxo IgG antibodies in human serum matrix. During manufacture, the analytes are spiked into the matrix at the desired concentration levels.

Intended use For use in the verification of the calibration established by the Elecsys Toxo IgG reagent on the Elecsys and cobas e immunoassay analyzers.

Continued on next page

510(k) Summary, Continued

Comparison Table

The table below compares Elecsys Toxo IgG CalCheck with the predicate device, Elecsys C-Peptide Calcheck (K040157).

Characteristic	Elecsys C- Peptide CalCheck (K040157)	Elecsys Toxo IgG CalCheck
Intended Use	For use in the verification of the calibration established by the Elecsys C-Peptide reagent on the Elecsys and cobas e immunoassay analyzers.	For use in the verification of the calibration established by the Elecsys Toxo IgG reagent on the Elecsys and cobas e immunoassay analyzers.
Levels	Three	Same
Format	Lyophilized	Same
Handling	Reconstitute with exactly 1.0 mL distilled or deionized water and allow standing closed for 15 minutes, then mixing gently.	Same
Stability	<u>Unopened:</u> <ul style="list-style-type: none">• Store at 2-8°C until expiration date <u>Reconstituted:</u> <ul style="list-style-type: none">• 20 – 25 °C : 4 hrs	Same
Matrix	equine serum matrix	Human serum

Performance Characteristics

The Elecsys Toxo IgG CalCheck was evaluated for value assignment and stability.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Ms. Kelly French
Regulatory Affairs Consultant
Roche Diagnostics
9115 Hague Road
Indianapolis, IN 46250-3831

FEB 12 2009

Re: K083655
Trade/Device Name: Elecsys Toxo IgG CalCheck
Regulation Number: 21 CFR 862.1660
21 CFR 866.3780
Regulation Name: Quality control material (assayed and unassayed)
Toxoplasma gondii serological reagents
Regulatory Class: I, II
Product Code: JJX, LGD
Dated: December 9, 2008
Received: December 10, 2008

Dear Ms. French:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,



Sally A. Hojvat, M.Sc., Ph.D.

Director

Division of Microbiology Devices

Office of *In Vitro* Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

Indication for Use

510(k) Number (if known): K083655

Device Name: **Elecsys Toxo IgG CalCheck**

Indication For Use:

The Elecsys Toxo IgG CalCheck, as assayed calibrator control, is intended for use in the verification of the calibration established by the Elecsys Toxo IgG reagent on the Elecsys 2010, the MODULAR ANALYTICS E170, and cobas e immunoassay analyzers.


Prescription Use X
(21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use _____
(21 CFR Part 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)



Division Sign-Off
Office of In Vitro Diagnostic Device
Evaluation and Safety

510(k) K083655